Lakefront Biotherapeutics (LKFT) FCF Margin (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly FCF Margin of 1457.94% for Q1 2026, down 140740.0% year-on-year from N/an in Q1 2025, and down 12771.88% on a QoQ basis from 11.33% in Q4 2025.
Lakefront Biotherapeutics (LKFT) FCF Margin (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported FCF Margin for 12 consecutive years, with 1457.94% the latest figure, recorded in Q1 2026.
- Quarterly FCF Margin fell 140740.0% year-over-year to 1457.94% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 18.16% (up 5126.0% YoY) and the FY2025 annual result came in at 28.91%, up 12852.0% from the prior year.
- FCF Margin fell to 1457.94% in Q1 2026 per LKFT's latest filing, from 11.33% in the prior quarter.
- Over the last five years, FCF Margin for LKFT reached as high as 6.36% in Q2 2025 and fell as low as 1457.94% in Q1 2026.
- A 5-year average of 275.36% and a median of 116.29% in 2023 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2025 — FCF Margin jumped 107813 bps — and 2026, when it tumbled 140740 bps.
- Year by year, FCF Margin stood at 125.61% in 2022, then increased by 7 bps to 116.29% in 2023, then tumbled by 837 bps to 1089.45% in 2024, then jumped by 99 bps to 11.33% in 2025, then slumped by 12772 bps to 1457.94% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 1457.94%, 11.33%, and 4.01% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lakefront Biotherapeutics | 1.85 Bn | -1.64 Bn | 1.91 Mn | -1,457.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,457.94% |
| Dec 31, 2025 | -11.33% |
| Sep 30, 2025 | 4.01% |
| Jun 30, 2025 | 6.36% |
| Mar 31, 2025 | -50.54% |
| Dec 31, 2024 | -1,089.45% |
| Sep 30, 2024 | 2.24% |
| Jun 30, 2024 | -6.49% |
| Mar 31, 2024 | -209.78% |
| Dec 31, 2023 | -116.29% |
| Mar 31, 2023 | -158.48% |
| Dec 31, 2022 | -125.61% |
| Mar 31, 2022 | -366.32% |
| Jun 30, 2020 | -136.35% |
| Mar 31, 2020 | -65.00% |
| Dec 31, 2019 | -142.66% |
| Sep 30, 2019 | 462.70% |
| Jun 30, 2019 | -117.53% |
| Mar 31, 2019 | -214.31% |
| Dec 31, 2018 | -50.69% |